Skip to main content
QMSQMS
QMS
  • Welcome to your QMS
  • Quality Manual
  • Procedures
  • Records
  • Legit.Health Plus Version 1.1.0.0
    • Index
    • Overview and Device Description
    • Information provided by the Manufacturer
    • Design and Manufacturing Information
      • R-TF-012-019 SOUPs
      • R-TF-012-028 Software Requirement Specification
      • R-TF-012-029 Software Architecture Description
      • R-TF-012-030 Software Configuration Management Plan
      • R-TF-012-031 Product requirements specification
      • R-TF-012-037 Labeling and IFU Requirements
      • R-TF-012-040 Documentation level FDA
      • R-TF-012-041 Software Classification 62304
      • R-TF-012-043 Traceability Matrix
      • Review meetings
        • Phase 1: Product Design Review
        • Phase 2: Software Design Review
        • Phase 3: Software Development Review (Release Candidate)
        • Phase 4: Software Verification Review
        • Phase 5: Product Validation Review
    • GSPR
    • Benefit-Risk Analysis and Risk Management
    • Product Verification and Validation
    • Post-Market Surveillance
  • Legit.Health Plus Version 1.1.0.1
  • Licenses and accreditations
  • Applicable Standards and Regulations
  • Pricing
  • Public tenders
  • Legit.Health Plus Version 1.1.0.0
  • Design and Manufacturing Information
  • Review meetings
  • Phase 4: Software Verification Review

Phase 4: Software Verification Review

Process Overview​

The purpose of the Software Verification review (Phase 4) is to ensure that all verification testing has been completed, test results have been documented, and residual anomalies have been assessed. This review validates that the software meets all specified requirements and is ready to proceed to Phase 5 (Product Validation).

According to GP-012, Phase 4 executes systematic testing to verify that the software implementation meets the Software Requirements Specification (SRS) and that any residual anomalies are acceptable.

General Information​

Information
Device nameLegit.Health Plus (hereinafter, the device)
Model and typeNA
Version1.1.0.0
Basic UDI-DI8437025550LegitCADx6X
Certificate number (if available)MDR 792790
EMDN code(s)Z12040192 (General medicine diagnosis and monitoring instruments - Medical device software)
GMDN code65975
EU MDR 2017/745Class IIb
EU MDR Classification ruleRule 11
Novel product (True/False)TRUE
Novel related clinical procedure (True/False)TRUE
SRNES-MF-000025345

Project Information​

  • Project title: Legit.Health Plus Version 1.1.0.0
  • Project manager: JD-007 (Technical Manager)
  • Review date: [Date to be completed]
  • Reviewers: JD-001 (General Manager), JD-003 (Design & Development Manager), JD-007 (Technical Manager), JD-004 (Quality Manager & PRRC)

Planning​

PhaseObjectDone
Phase 1 Product Design ReviewEstablish input data✓
Phase 2 Software Design ReviewSRs, Architectural Design and UI Prototypes✓
Phase 3 Software DevelopmentCoding, integration and test plan✓
Phase 4 Software Verification ReviewSoftware version verified and residual anomalies✓
Phase 5 Product Validation ReviewValidation activities, Technical Documentation and DHF

Previous Reserves​

All reserves from Phase 3 have been addressed and closed.

N°Issue from Phase 3ResolutionStatus
-No reserves--

Verification Testing Summary​

Test Execution Overview​

Test CategoryTotal TestsPassedFailedBlockedPass RateReference
Software Requirements Tests[Number][#][#][#][%]R-TF-012-035
Integration Tests[Number][#][#][#][%]R-TF-012-035
System Tests[Number][#][#][#][%]R-TF-012-035
Regression Tests[Number][#][#][#][%]R-TF-012-035
Total[#][#][#][#][%]

Verification Documents​

DocumentStatusReferenceComments
Software Test Plan✓R-TF-012-033Test strategy followed
Software Test Description✓R-TF-012-034Test procedures executed as documented
Software Test Report✓R-TF-012-035All test results documented
Verified Version Release✓R-TF-012-038Verified version description complete

IEC 62304 Compliance Review​

Software Unit Verification (5.5)​

RequirementStatusEvidenceComments
5.5.2 Unit verification strategies documented✓R-TF-012-033Unit testing strategy defined
5.5.3 Unit acceptance criteria documented✓Acceptance criteria defined in test planCriteria clear and verifiable
5.5.5 Unit verification results documented✓R-TF-012-035Unit test results recorded

Software Integration and Integration Testing (5.6)​

RequirementStatusEvidenceComments
5.6.1 Software units integrated per plan✓Integration performed according to architectureIntegration strategy followed
5.6.2 Integration verification documented✓R-TF-012-035Integration tests executed
5.6.3-5.6.4 Integration testing documented✓R-TF-012-035Integration test results recorded
5.6.5 Test procedures validity evaluated✓Test procedures reviewed and approvedProcedures verified as valid
5.6.6-5.6.7 Regression tests performed✓Regression testing completed to verify no new defectsRegression suite passed
5.6.8 Anomalies in problem resolution process✓All anomalies tracked in GitHub IssuesProblem resolution process followed

Software System Testing (5.7)​

RequirementStatusEvidenceComments
5.7.1, 5.7.4, 5.7.5 System tests executed✓R-TF-012-035All system tests completed
5.7.2 Anomalies in problem resolution✓Defects tracked and resolved via GitHub IssuesIssue tracking maintained
5.7.3 Modifications during testing handled✓Changes managed through change controlConfiguration management maintained

Software Release (5.8)​

RequirementStatusEvidenceComments
5.8.1 Verification completed and evaluated✓R-TF-012-035All verification activities completed
5.8.2 Known residual anomalies documented✓See Residual Anomalies section belowAll anomalies documented
5.8.3 Residual anomalies risk assessed✓Risk assessment performed for each anomalyAll anomalies acceptable
5.8.4 Software version documented✓R-TF-012-038Version 1.1.0.0 documented
5.8.5-5.8.8 Release procedures documented✓Release process documented in R-TF-012-023Build and release procedures defined
5.8.6 All activities and tasks completed✓DHF review confirms completionDevelopment activities complete

IEC 81001 (Cybersecurity) Compliance Review​

Implementation Reviews (5.5.2)​

RequirementStatusEvidenceComments
Implementation reviews for security issues✓Security code reviews performedSecurity implementation verified
Security issues in problem resolution process✓Security vulnerabilities tracked and resolvedSecurity defects managed

Software Integration Testing (5.6)​

RequirementStatusEvidenceComments
Security testing as part of integration✓Security integration tests executedSecurity controls verified during integration

Software System Security Testing (5.7)​

RequirementStatusEvidenceComments
5.7.1 Security requirements testing✓R-TF-030-004Security functions verified
5.7.2 Threat mitigation testing✓R-TF-030-004Threat mitigations tested
5.7.3 Vulnerability testing✓R-TF-030-004Vulnerability scans performed
5.7.4 Penetration testing✓R-TF-030-004Penetration tests conducted
5.7.4 Objectivity of security testing✓Testing performed by independent security teamTest independence maintained

Requirements Traceability Verification​

ActivityStatusEvidenceComments
All SRS traced to test cases✓Traceability matrix in R-TF-012-023Complete SRS → Test Case traceability
All test cases executed✓R-TF-012-035100% test execution
All SRS verified✓Test results demonstrate SRS satisfactionAll requirements verified
Risk control measures verified✓Controls from R-TF-013-002 testedRisk controls functioning as intended
Security controls verified✓Controls from R-TF-030-003 testedSecurity controls effective

AI/ML Verification​

ActivityStatusEvidenceComments
AI/ML model performance testing✓R-TF-028-005Model performance meets requirements
AI/ML integration verification✓ML models integrated and tested in systemIntegration successful
AI/ML risk assessment✓R-TF-028-011AI-specific risks assessed

Residual Anomalies​

All known residual anomalies have been documented, risk assessed, and determined to be acceptable.

IDSeveritySummaryRisk Assessment & Control MeasureAcceptabilityStatus
[ID][Level][Description][Risk analysis and justification][Acceptable/Not Acceptable][Open/Closed]
--No critical or high severity anomalies---

Risk Assessment Summary:

  • All residual anomalies have been evaluated per ISO 14971 risk management process
  • No residual anomalies contribute to unacceptable risk
  • All anomalies are documented in risk management record R-TF-013-002
  • Benefits outweigh residual risks for all anomalies

Design History File (DHF) Status​

ItemStatusComments
All verification records complete✓Test reports and results documented
Traceability matrix updated✓Complete traceability: PR → SRS → Test Cases → Test Results
Anomaly records complete✓All defects tracked with resolution
DHF index updated✓All documents indexed and accessible
Version release documentation complete✓R-TF-012-038

Compliance Checklists​

ChecklistStatusReference
IEC 62304 Compliance Checklist✓EN-62304-Checklist
IEC 82304-1 Compliance Checklist✓EN-82304-Checklist

Reserves and Pending Actions​

N°Issue / Action RequiredOwnerTargeted DateStatus
-No reserves identified at this phase---

Conclusion​

Review Outcome: The Phase 4 Software Verification review has been successfully completed.

Assessment:

  • All verification testing has been completed according to the Software Test Plan
  • Test results are documented in the Software Test Report R-TF-012-035
  • All Software Requirements have been verified through testing
  • Requirements traceability is complete (PR → SRS → Test Cases → Test Results)
  • IEC 62304 verification requirements (5.5, 5.6, 5.7, 5.8) are satisfied
  • IEC 81001 cybersecurity testing requirements are satisfied
  • All risk control measures have been verified as implemented and effective
  • All security controls have been verified and are functioning correctly
  • AI/ML components have been verified and meet performance requirements
  • Residual anomalies have been documented and risk assessed
  • All residual anomalies are acceptable and do not contribute to unacceptable risk
  • Design History File is complete and up to date
  • Verified Version Release documentation is complete

Risk Analysis of Residual Anomalies: All known residual anomalies have been evaluated according to ISO 14971. None of the residual anomalies contribute to unacceptable risk. Risk controls are in place and have been verified as effective.

Regarding the mentioned reserves, has the review been accepted?: Yes

Decision: The verified software version 1.1.0.0 is approved to proceed to Phase 5: Product Validation.

Next Steps:

  • Initiate Product Validation activities
  • Complete summative usability testing per R-TF-025-001
  • Finalize clinical evaluation per R-TF-015-008
  • Complete AI/ML release report R-TF-028-006
  • Finalize all procedure reports (risk management, cybersecurity, usability, clinical)
  • Prepare for final Product Validation review and commissioning

Approved by:

Signature meaning

The signatures for the approval process of this document can be found in the verified commits at the repository for the QMS. As a reference, the team members who are expected to participate in this document and their roles in the approval process, as defined in Annex I Responsibility Matrix of the GP-001, are:

  • Author: Team members involved
  • Reviewer: JD-003, JD-004
  • Approver: JD-001
Previous
Phase 3: Software Development Review (Release Candidate)
Next
Phase 5: Product Validation Review
  • Process Overview
  • General Information
  • Project Information
  • Planning
  • Previous Reserves
  • Verification Testing Summary
    • Test Execution Overview
    • Verification Documents
  • IEC 62304 Compliance Review
    • Software Unit Verification (5.5)
    • Software Integration and Integration Testing (5.6)
    • Software System Testing (5.7)
    • Software Release (5.8)
  • IEC 81001 (Cybersecurity) Compliance Review
    • Implementation Reviews (5.5.2)
    • Software Integration Testing (5.6)
    • Software System Security Testing (5.7)
  • Requirements Traceability Verification
  • AI/ML Verification
  • Residual Anomalies
  • Design History File (DHF) Status
  • Compliance Checklists
  • Reserves and Pending Actions
  • Conclusion
All the information contained in this QMS is confidential. The recipient agrees not to transmit or reproduce the information, neither by himself nor by third parties, through whichever means, without obtaining the prior written permission of Legit.Health (AI Labs Group S.L.)